More NIST supplement standards on the way
This article was originally published in The Tan Sheet
Executive Summary
The National Institute of Standards and Technology soon will offer standard reference material and certificates of analysis for a berry suite, including cranberries, bilberries and blueberries, a green tea suite and tocopherols in edible oil. NIST has other dietary supplement materials in the acquisition phase, including St. John's Wort, pomegranate and turmeric, said NIST research chemist Kate Rimmer. NIST prioritizes SRM development based on safety concerns and market share for particular supplements, Rimmer said Nov. 11 at the SupplySide West trade show and conference in Las Vegas. The Department of Commerce agency sells the reference substances to manufacturers looking to develop or calibrate lab validation methods. NIST recently began offering an SRM for vitamin D in human serum (1"The Tan Sheet" Oct. 12, 2009, In Brief)
You may also be interested in...
NIST offers Vitamin D SRM
The National Institute of Standards and Technology offers a new standard reference material, SRM 972, for vitamin D in human serum. The material will help labs more accurately measure patients' vitamin D levels so physicians can diagnose accurately when people are deficient, NIST said. It added physicians are testing vitamin D levels more in part because recent studies link low levels of vitamin D to increased risk of certain diseases (1"The Tan Sheet" June 1, 2009)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.